We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: February 1, 2010
Last Update Posted: July 27, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
The objective of this study is to evaluate the formation of antibodies, the occurence of allergic reactions, and the risk of hypercoagulability and hypocoagulability in patients treated with KALBITOR (ecallantide).

Condition Intervention
Hereditary Angioedema Drug: ecallantide

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Phase 4, Long-Term Observational Safety Study to Evaluate Immunogenicity and Hypersensitivity With Exposure to KALBITOR (Ecallantide) for the Treatment of Acute Attacks of HAE

Resource links provided by NLM:

Further study details as provided by Shire:

Primary Outcome Measures:
  • Occurrence of Anaphylaxis or Other Adverse Events Suggestive of Hypersensitivity [ Time Frame: 12 months after first treatment ]
    Based on medical review of multiple preferred terms for treatment emergent adverse events (TEAEs) suggestive of Type 1 hypersensitivity; terms included adverse drug reaction, anaphylaxis, anaphylactic reaction, anaphylactoid reaction, hypersensitivity, erythema, flushing, hot flush, pharyngeal edema, laryngeal edema, pruritus, pruritus generalized, rash, rash erythematous, rhinitis allergic, rhinorrhea, throat irritation, urticaria, urticaria localized, dyspnea, and wheezing. Records of patients with any of these TEAE referred terms were reviewed further to assess potential hypersensitivity reactions, considering factors such as timing of TEAEs in relationship to dose (ie, occurred within 24 hours after start of KALBITOR treatment), accompanying symptoms, Investigator causality assessment (ie, reported as possibly, probably, or definitely related to study drug), and any other available clinical information. Anaphylaxis subset determined based on criteria established by the NIAID.

  • Occurrence of Seroconversion to Anti-ecallantide Antibodies Upon Exposure to KALBITOR. [ Time Frame: 12 months after first treatment ]

    Seroconversion is the development of detectable specific antibodies in the blood serum. Serum was tested for development of antibodies (irrespective of immunoglobulin class) against ecallantide at screening and at all safety evaluations. Positive results were to undergo a confirmatory test. Confirmed positive samples were further titered. Patients who developed an antibody response were evaluated for the development of neutralizing antibodies.

    Patients also had their serum analyzed for IgE-specific antibodies to ecallantide at screening and during safety evaluations. Positive results underwent a confirmatory test. Confirmed positive samples were further titered.

  • Occurrence of Adverse Events Related to Disordered Coagulation (Hypercoagulability and Hypocoagulability) Upon Exposure to KALBITOR [ Time Frame: 12 months after first treatment ]
    Events of ecchymosis, hemorrhage, petechiae, spontaneous hemorrhage, hematoma, gastrointestinal bleeding, hemorrhagic stroke and any other term indicative of a bleeding event or increased tendency for bleeding were reviewed to determine the occurrence of hypocoagulability. Events of clotting, thrombosis, pulmonary embolism, vaso-occlusive stroke, myocardial infarction, and any other term indicative of a clotting event or increased risk of clotting were reviewed to determine the occurrence of hypercoagulability.

Secondary Outcome Measures:
  • Overall Patient Response Assessment [ Time Frame: within 4 hours post dose ]
    The Overall Response Assessment was to be completed every 30 minutes after treatment until patient discharge. Patients evaluated their response to treatment as "a lot better or resolved," "a little better," "the same," "a little worse," or "a lot worse." The data presented is based on the best response achieved following a single dose of KALBITOR (Dose A) for the first HAE treatment episode. Responses of "a lot better or resolved" and "a little better" were combined to form a category of "Better." Similarly, "a little worse" and "a lot worse" were combined to form a category of "Worse." Patients treated in a clinic (study site) could have been discharged after an hour and hence may have only had 2 post-treatment evaluations (30 and 60 minutes); response assessments may not have been consistently provided when patients were treated at an alternate site outside of the study site.

Biospecimen Retention:   Samples Without DNA

Enrollment: 81
Study Start Date: February 2010
Study Completion Date: June 2014
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Patients naive to KALBITOR
HAE patients that have not been treated with KALBITOR (ecallantide) prior to enrollment in the study
Drug: ecallantide
30 mg SC
Other Name: Kalbitor
Patients non- naive to KALBITOR
HAE patients that have been treated with KALBITOR prior to enrollment in the study
Drug: ecallantide
30 mg SC
Other Name: Kalbitor

Detailed Description:

The objective of this study is to evaluate immunogenicity and hypersensitivity upon exposure to KALBITOR, in particular:

  1. Determine the rate of anaphylaxis and Type I hypersensitivity reactions upon exposure to KALBITOR.
  2. Determine the rate of seroconversion to anti-ecallantide antibodies upon exposure to KALBITOR.
  3. Determine the rate of adverse events related to disordered coagulation (hypercoagulability and hypocoagulability) upon exposure to KALBITOR.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   16 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients with hereditary angioedema, either naive or non-naive to KALBITOR (ecallantide) prior to enrollment in the study

Inclusion Criteria:

  • Patients indicated per the approved product label for KALBITOR
  • Patient or guardian is able to understand and sign the informed consent form
  • Patient is willing and able to undergo a skin test procedure at screening (baseline)

Exclusion Criteria:

  • Patient contraindicated per the approved product label for KALBITOR
  • Patient confirmed pregnancy or active breastfeeding
  • Any other condition that, in the opinion of the Investigator, may compromise the safety or compliance of the patient or would preclude the patient from successful completion of the study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01059526

  Hide Study Locations
United States, Arkansas
Little Rock Allergry and Asthma Clinical Research Center
Little Rock, Arkansas, United States, 72205
United States, California
Sunrise Clinical Research
Bell Gardens, California, United States, 90201
Allergy & Asthma Institute of the Valley
Granada Hills, California, United States, 91344
Unidversity of California, Los Angeles David Geffen School of Medicine
Los Angeles, California, United States, 90095-1680
705 West LaVeta
Orange, California, United States, 92868
Allergy & Asthma Clinical Research Inc.
Walnut Creek, California, United States, 94598
United States, Connecticut
Center for Allergy, Asthma & Immunology
Waterbury, Connecticut, United States, 06708
United States, Florida
University of South Florida Asthma
Tampa, Florida, United States, 33613
United States, Georgia
Brookstone Clinical Research Center
Columbus, Georgia, United States, 31904
United States, Illinois
University Consultants in Allergry and Immunology
Chicago, Illinois, United States, 60612
United States, Indiana
Deaconess Clinic Downtown
Evansville, Indiana, United States, 47713
Muncie Allergy Ctr
Muncie, Indiana, United States, 47304
United States, Kansas
Kansas City Allergy and Asthma Associates
Overland Park, Kansas, United States, 66210
United States, Louisiana
Ochsner Health System - Allergy, Asthma and Immunology Department
Jefferson, Louisiana, United States, 70121
Clinical Research Specialists
Metairie, Louisiana, United States, 70006
United States, Maryland
Institute for Asthma and Allergy, P.C.
Chevy Chase, Maryland, United States, 20815
United States, Massachusetts
Brigham and Women's Hospital
Chestnut Hill, Massachusetts, United States, 02467
United States, Michigan
University of Michigan Health System Allergy Specialty Clinic
Ann Arbor, Michigan, United States, 48105
Asthma and Allergy Institute of Michigan
Clinton Township, Michigan, United States, 48038
United States, Missouri
Saint Louis University School of Medicine
St. Louis, Missouri, United States, 63104
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
United States, Nevada
University of Nevada School of Medicine - Department of Pediatrics
Reno, Nevada, United States, 89503
United States, New Jersey
Allergy Treatment Center of New Jersey
Iselin, New Jersey, United States, 08830
United States, New York
Bronx, New York, United States, 10465
Winthrop University Hospital
Mineola, New York, United States, 11501
Medical Research Associates of CNY
North Syracuse, New York, United States, 13212
United States, North Carolina
Allergy Partners of Western North Carolina
Ashville, North Carolina, United States, 28801
Specialty Medical Clinic And Research Center
Sanford, North Carolina, United States, 27330
United States, Ohio
Department of Internal Medicine, University of Cincinnati -MSB
Cincinnati, Ohio, United States, 45267-0563
Optimed Research, LTD
Columbus, Ohio, United States, 43235
Reynolds Clinic
Toledo, Ohio, United States, 43615
Toledo Institute of Clinical Research
Toledo, Ohio, United States, 43617
United States, Oklahoma
Allergy Clinic of the Tulsa, Inc.
Tulsa, Oklahoma, United States, 74133
United States, Pennsylvania
Penn State University - Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States, 17033-0850
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania, United States, 15224
United States, Texas
AARA Research Center
Dallas, Texas, United States, 75231
United States, Utah
University of Utah, Department of Dermatology
Salt Lake City, Utah, United States, 84132
United States, Virginia
Children's Hospital of the King's Daughters
Norfolk, Virginia, United States, 23507
Virginia Beach, Virginia, United States, 23452
United States, Washington
Puget Sound Allergy, Asthma and Immunology
Tacoma, Washington, United States, 98405
Sponsors and Collaborators
Study Director: Yung Chyung, MD Dyax Corp.
  More Information

Responsible Party: Shire
ClinicalTrials.gov Identifier: NCT01059526     History of Changes
Other Study ID Numbers: DX-88/24
First Submitted: January 28, 2010
First Posted: February 1, 2010
Results First Submitted: September 10, 2014
Results First Posted: October 6, 2014
Last Update Posted: July 27, 2016
Last Verified: June 2016

Keywords provided by Shire:

Additional relevant MeSH terms:
Angioedemas, Hereditary
Vascular Diseases
Cardiovascular Diseases
Skin Diseases, Vascular
Skin Diseases
Hypersensitivity, Immediate
Immune System Diseases
Genetic Diseases, Inborn